Thermo Fisher Scientific
About Thermo Fisher Scientific
Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue of approximately $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer.
Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them.
Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD.
Stock Symbol: TMO
1613 articles with Thermo Fisher Scientific
-
Stevanato Group Collaborates with Thermo Fisher Scientific to Bring its Innovative On-Body Delivery System Platform to Market
3/21/2023
Stevanato Group S.p.A. announced its collaboration with Thermo Fisher Scientific, the world leader in serving science, to bring to the market a fully integrated on-body delivery system platform for subcutaneous administration.
-
Thermo Fisher Scientific to Present at Cowen 43rd Annual Healthcare Conference on March 6, 2023
2/28/2023
Thermo Fisher Scientific Inc. will present at the Cowen Healthcare Conference on Monday, March 6, 2023 at 9:10 a.m. (EST).
-
Thermo Fisher Scientific Increases Quarterly Dividend - February 22, 2023
2/22/2023
Thermo Fisher Scientific Inc., the world leader in serving science, announced that its Board of Directors has authorized a quarterly cash dividend of $0.35 per common share payable on April 14, 2023, to stockholders of record as of March 15, 2023.
-
Thermo Fisher Scientific Selected to Support National Institute of Health’s Blueprint MedTech program
2/21/2023
The PPD clinical research business of Thermo Fisher Scientific Inc., the world leader in serving science, has been awarded a five-year contract to provide regulatory affairs support and related services for the Blueprint MedTech (BPMT) program, a new multi-institute/center initiative at the National Institutes of Health (NIH) supporting development of translational neurological devices.
-
Thermo Fisher Scientific Launches TrueMark STI Select Panel
2/8/2023
Thermo Fisher Scientific, the world leader in serving science, today announced the launch of its Applied Biosystems TrueMark STI Select Panel, a polymerase chain reaction (PCR) research use only test designed to detect Chlamydia trachomatis, Neisseria gonorrhoeae, Trichomonas vaginalis and Mycoplasma genitalium in one test, as well as RNase P, included as a human internal control.
-
Elektrofi Announces Collaboration with Thermo Fisher Scientific to Strengthen Manufacturing Capabilities for Future Clinical Trials
2/7/2023
Elektrofi, a biotechnology company focused on drug formulation and delivery innovations, announced a strategic contract manufacturing agreement with Thermo Fisher Scientific to support clinical manufacture of Elektrofi’s breakthrough ultra-high concentration subcutaneous products.
-
Thermo Fisher Scientific to Power All Current U.S. Sites With 100 Percent Renewable Electricity
2/2/2023
Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced it will power all of the company’s current U.S. sites with 100 percent renewable electricity by 2026.
-
Bronwyn Brophy is appointed new CEO of Vitrolife AB (publ)
2/1/2023
Bronwyn Brophy is Irish and has extensive experience of leading positions in Global Life Science and Medtech companies such as Thermo Fisher Scientific, Medtronic and Johnson & Johnson.
-
Thermo Fisher Scientific Reports Fourth Quarter and Full Year 2022 Results
2/1/2023
Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today reported its financial results for the fourth quarter and full year ended December 31, 2022.
-
The pharmaceutical industry is expected to spend more than $3 billion on artificial intelligence by 2025, but advocates say it is not yet living up to its potential.
-
Thermo Fisher Scientific Partners with AstraZeneca to Develop Solid Tissue and Blood-Based Companion Diagnostic Test for Tagrisso
1/24/2023
Thermo Fisher Scientific Partners with AstraZeneca to Develop Solid Tissue and Blood-Based Companion Diagnostic Test for Tagrisso.
-
Thermo Fisher Scientific Launches CE-IVD Marked Assay to Detect Treatment-Resistant Strains of HIV-1
1/23/2023
Thermo Fisher Scientific, the world leader in serving science, today announced the launch of its CE-IVD marked Applied Biosystems TaqPath Seq HIV-1 Genotyping Kit, a Sanger sequencing-based assay that examines positive samples of human immunodeficiency virus (HIV) to identify genetic variants that may resist common antiretroviral therapeutics.
-
Thermo Fisher Scientific Joins Momentum Labs as Founding Sponsor of New Biotech Hub in Alachua, Florida
1/12/2023
As part of its efforts to support emerging biotechnology companies with addressing key challenges of bringing new therapies to market, Thermo Fisher Scientific today announced it has become a founding sponsor of Momentum Labs in Alachua, Fla.
-
Thermo Fisher Scientific to Present at 41st Annual J.P. Morgan Healthcare Conference on January 10, 2023
1/4/2023
Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced that Marc N. Casper, chairman, president and chief executive officer, will present at the 41st Annual J.P. Morgan Healthcare Conference on Tuesday, January 10, 2023, at 10:30 a.m. (EST).
-
Thermo Fisher Scientific Completes Acquisition of The Binding Site Group
1/3/2023
Thermo Fisher Scientific Inc. today announced that it has completed its acquisition of The Binding Site Group (“The Binding Site”), a global leader in specialty diagnostics, from a shareholder group led by European private equity firm Nordic Capital, in an all-cash transaction valued at £2.3 billion, or $2.8 billion at current exchange rates.
-
Thermo Fisher Scientific to Hold Earnings Conference Call on Wednesday, February 1, 2023
1/3/2023
Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced that it will release its financial results for the fourth quarter and full year 2022 before the market opens on Wednesday, February 1, 2023, and will hold a conference call on the same day at 8:30 a.m. EST.
-
ASLAN Pharmaceuticals and Thermo Fisher Scientific Announce Partnership to Manufacture High Concentration Formulation of Eblasakimab for Future Studies
1/3/2023
ASLAN Pharmaceuticals and Thermo Fisher Scientific Inc (NYSE: TMO), the world leader in serving science, today announced a partnership to manufacture a high concentration formulation of eblasakimab for Phase 3 clinical trials.
-
Thermo Fisher Scientific’s Advanced Analytical Instruments Receive R&D 100 Awards
12/15/2022
Thermo Fisher Scientific Inc., the world leader in serving science, received R&D 100 Awards from R&D World Magazine for two of its most recently launched analytical instruments.
-
FDA Grants Emergency Use Authorization for Thermo Fisher Scientific’s Monkeypox Test
12/14/2022
Thermo Fisher Scientific, the world leader in serving science, today announced the U.S. Food and Drug Administration (FDA) has granted Emergency Use Authorization (EUA) for its Applied Biosystems TaqPath Monkeypox/Orthopox Virus DNA Kit, a polymerase chain reaction (PCR) test designed to detect non-variola Orthopoxviruses, including monkeypox virus, in approximately three-and-a-half hours.
-
FDA Grants De Novo Classification to HLA Typing Test for Use as a Companion Diagnostic with a T Cell Receptor Therapy for Metastatic or Unresectable Uveal Melanoma
12/7/2022
Thermo Fisher Scientific Inc. today announced that its SeCore CDx HLA Sequencing System was granted De Novo Classification by the United States Food and Drug Administration (FDA) for use as a companion diagnostic with KIMMTRAK ®.